您好，欢迎来到试剂信息网！ [登录] [免费注册]
试剂信息网
发布求购
位置：首页 > 产品库 > ANT3310 sodium
立即咨询
咨询类型：
     
*姓名：
*电话：
*单位：
Email：
*留言内容：
请详细说明您的需求。
*验证码：
 
ANT3310 sodium
本产品不向个人销售，仅用作科学研究，不用于任何人体实验及非科研性质的动物实验。
ANT3310 sodium图片
CAS NO:2410688-61-6
包装与价格：
包装价格(元)
10mg电议
25mg电议
50mg电议
100mg电议

产品介绍
ANT3310 sodium 是一种广谱的、共价的丝氨酸 β-内酰胺酶 (Serine β-Lactamase) 抑制剂，IC50 值为 1 nM-175 nM (一系列丝氨酸β-内酰胺酶)。ANT3310 sodium 增强 β-内酰胺类抗生素对耐碳青霉烯类肠杆菌 (CRE) 和鲍曼不动杆菌 (CRAB) 的活性。ANT3310 sodium 可用于细菌感染相关的研究。
Cas No.2410688-61-6
分子式C6H8FN2NaO5S
分子量262.19
溶解度DMSO : 250 mg/mL (953.51 mM; Need ultrasonic)
储存条件Store at -20°C
General tipsFor obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.
Shipping ConditionEvaluation sample solution : ship with blue ice
All other available size: ship with RT , or blue ice upon request
产品描述

ANT3310 sodium is a broad-spectrum covalentSerine β-Lactamaseinhibitor, withIC50values ranging from 1 nM to 175 nM (a panel of Serine β-Lactamase). ANT3310 sodium potentiates activity of β-lactam antibiotics against Carbapenem-Resistant Enterobacterales (CRE) andAcinetobacter baumannii(CRAB). ANT3310 sodium can be used in the research of bacterial infection[1][2].

ANT3310 sodium (Compound 21, 0.006 to 3 000 nM, 10 min) inhibits a series of Serine β-Lactamase (AmpC, CTX-M-15, TEM-1, OXA-48, OXA-23, and KPC-2), with IC<>50values ranging from 1 nM to 175 nM[1].
ANT3310 sodium shows a lowin vitrocytotoxicity (IC<>50: > 100 μM) in HepG2 cell, cardiotoxicity (inhibition of the hERG potassium ion channel), and genotoxicity (Ames test)[1].

ANT3310 sodium (intravenous injection, 25-100 mg/kg, at 1, 3, 5, and 7 h postinfection) reduces bacterial burdens in murine thigh infection model[1].
ANT3310 sodium (intravenous injection, 1 mg/kg, Male Swiss albino mice) shows a T1/2value of 0.64 h, AUC value of 412 ng•h/mL, and Cl value of 40 mL/min/kg (pharmacokinetic assay)[1].

Animal Model:Murine thigh infection model[1]
Dosage:25, 50, and 100 mg/kg
Administration:Intravenous injection, at 1, 3, 5, and 7 h postinfection
Result:Reduced bacterial burdens (colony forming units, CFU) in a dose-dependent manner to levels below that of the initial starting inoculum at the highest dose, when treated with the combination of MEM.